1. Home
  2. PRCH vs TSHA Comparison

PRCH vs TSHA Comparison

Compare PRCH & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Porch Group Inc.

PRCH

Porch Group Inc.

N/A

Current Price

$17.06

Market Cap

1.5B

Sector

Technology

ML Signal

N/A

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$5.97

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRCH
TSHA
Founded
2012
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PRCH
TSHA
Price
$17.06
$5.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
8
Target Price
$18.63
$11.63
AVG Volume (30 Days)
1.8M
2.6M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
5.56
EPS
0.01
N/A
Revenue
$482,414,000.00
$9,773,000.00
Revenue This Year
$4.15
N/A
Revenue Next Year
$17.05
$1,152.42
P/E Ratio
$1,709.00
N/A
Revenue Growth
10.18
17.28
52 Week Low
$6.36
$2.72
52 Week High
$19.44
$7.30

Technical Indicators

Market Signals
Indicator
PRCH
TSHA
Relative Strength Index (RSI) 65.65 48.53
Support Level $9.08 $5.28
Resistance Level N/A $6.76
Average True Range (ATR) 0.73 0.33
MACD 0.05 -0.02
Stochastic Oscillator 83.97 32.30

Price Performance

Historical Comparison
PRCH
TSHA

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: